‘Right To Try Laws’ and Legal Access to Psilocybin Therapy with Dr. Jonathan Fields
Petitioning the DEA to respect the ‘Right to Try Laws’ which empower terminally ill patients to legally access psilocybin therapy.
dea
Breaking: DEA Backs Off, Won’t Criminalize Two New Psychedelics
The DEA backs off announces they are withdrawing a proposed rule to ban the psychedelic drugs DOI and DOC, at least for now
The DEA is Attempting to Ban Two New Psychedelic Drugs
The DEA moves to ban two obscure psychedelic drugs, DOI and DOC, amidst ongoing calls to ease restrictions on psychedelic medicines
DEA Under Pressure from Terminally Ill “Right to Try” Psychedelic Advocates
The DEA is denying psilocybin therapy for dying patients despite the Right To Try Act. Here’s a timeline of the fight to access to psychedelic therapy for terminally ill patients
The DEA Backs Down, Will Not Criminalize 5 Psychedelics
This week the DEA announced it would withdraw its plan to schedule 5 research psychedelics. But we shouldn’t celebrate just yet
Judge Grants Hearing for Opposition to DEA Proposal to Criminalize 5 More Psychedelics
Biotech companies and researchers opposed to five more tryptamines becoming schedule 1 controlled substances will present their case this spring.
DEA Proposes Adding 5 More Psychedelics to Schedule 1 Controlled Substances
Agency argues these five tryptamines “have no known medical use,” setting up a showdown with the emerging psychedelics industry.
DEA Boosts Psychedelics Production (Again) to Meet Research Demand
Drug Enforcement Agency also addresses concerns from Native American Church regarding peyote poaching for mescaline research.
DEA Quadruples Psilocybin Manufacturing for Research in Final 2021 Production Quotas
Drug Enforcement Agency also hugely boosts MDMA and DMT quotas “in response to the nationwide public interest in hallucinogenic controlled substances research.”
DEA Proposes Huge Increase to Psilocybin and Psilocin Quotas for Research Purposes
In its proposed revised 2021 quotas, the DEA suggests 4900% increase in the allowed quantities of psilocybin for research and clinical trial purposes.
End of content
End of content